Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors

Open access
Thomas, Anish, Redon, Christophe E., Sciuto, Linda, Padiernos, Emerson, Ji, Jiuping, Lee, Min-Jung, Yuno, Akira, Lee, Sunmin, Zhang, Yiping, Tran, Lan, Yutzy, William, Rajan, Arun, Guha, Udayan, Chen, Haobin, Hassan, Raffit, Alewine, Christine C., Szabo, Eva, Bates, Susan E., Kinders, Robert J., Steinberg, Seth M., Doroshow, James H., Aladjem, Mirit I., Trepel, Jane B., Pommier, Yves·2018·Journal of Clinical Oncology

Abstract

Purpose: Our preclinical work identified depletion of ATR as a top candidate for topoisomerase 1 (TOP1) inhibitor synthetic lethality and showed that ATR inhibition sensitizes tumors to TOP1 inhibitors. We hypothesized that a combination of selective ATR inhibitor M6620 (previously VX-970) and topotecan, a selective TOP1 inhibitor, would be tolerable and active, particularly in tumors with high replicative stress. Patients and Methods: This phase I study tested the combination of M6620 and topotecan in 3-week cycles using 3 + 3 dose escalation. The primary end point was the identification of the maximum tolerated dose of the combination. Efficacy and pharmacodynamics were secondary end points. Results: Between September 2016 and February 2017, 21 patients enrolled. The combination was well tolerated, which allowed for dose escalation to the highest planned dose level (topotecan 1.25 mg/m 2 , days 1 to 5; M6620 210 mg/m 2 , days 2 and 5). One of six patients at this dose level experienced grade 4 thrombocytopenia that required transfusion, a dose-limiting toxicity. Most common treatment-related grade 3 or 4 toxicities were anemia, leukopenia, and neutropenia (19% each); lymphopenia (14%); and thrombocytopenia (10%). Two partial responses (≥ 18 months, ≥ 7 months) and seven stable disease responses ≥ 3 months (median, 9 months; range, 3 to 12 months) were seen. Three of five patients with small-cell lung cancer, all of whom had platinum-refractory disease, had a partial response or prolonged stable disease (10, ≥ 6, and ≥ 7 months). Pharmacodynamic studies showed preliminary evidence of ATR inhibition and enhanced DNA double-stranded breaks in response to the combination. Conclusion: To our knowledge, this report is the first of an ATR inhibitor-chemotherapy combination. The maximum dose of topotecan plus M6620 is tolerable. The combination seems particularly active in platinum-refractory small-cell lung cancer, which tends not to respond to topotecan alone. Phase II studies with biomarker evaluation are ongoing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.76.6915

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 171

Metadata

Authors
Thomas, A., Redon, C. E., Sciuto, L., Padiernos, E., Ji, J., Lee, M.-J., Yuno, A., Lee, S., Zhang, Y., Tran, L., Yutzy, W., Rajan, A., Guha, U., Chen, H., Hassan, R., Alewine, C. C., Szabo, E., Bates, S. E., Kinders, R. J., Steinberg, S. M., Doroshow, J. H., Aladjem, M. I., Trepel, J. B., & Pommier, Y.
Venue
Journal of Clinical Oncology
Published
2018-06-01
Volume
36
Issue
16
Pages
1594-1602
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2775990711
Cited by
171
References
7
FWCI
3.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. https://app.cochat.ai/papers/10.1200/jco.2017.76.6915
The paper
Thomas, A., Redon, C. E., Sciuto, L., Padiernos, E., Ji, J., Lee, M.-J., Yuno, A., Lee, S., Zhang, Y., Tran, L., Yutzy, W., Rajan, A., Guha, U., Chen, H., Hassan, R., Alewine, C. C., Szabo, E., Bates, S. E., Kinders, R. J., . . . Pommier, Y. (2018). Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.76.6915

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.